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Certain chemotherapeutic regimens trigger cancer cell
death while inducing dendritic cell maturation and sub-
sequent immune responses. However, chemotherapy-
induced immunogenic cell death (ICD) has thus far been
restricted to select agents. In contrast, several che-
motherapeutic drugs modulate antitumor immune
responses, despite not inducing classic ICD. In addition,
in many cases tumor cells do not die after treatment.
Here, using docetaxel, one of the most widely used can-
cer chemotherapeutic agents, as a model, we examined
phenotypic and functional consequences of tumor cells
that do not die from immunogenic cell death. Docetaxel
treatment of tumor cells did not induce ATP or HMGB1
secretion, or cell death. However, calreticulin exposure
was observed in all cell lines examined after chemother-
apy treatment. Killing by CEA, MUC-1, or PSA-specific
CD8+ CTLs was significantly enhanced after docetaxel
treatment. This killing was associated with increases in
components of antigen-processing machinery, and
mediated largely by calreticulin membrane translocation,
as determined by functional knockdown of calreticulin,
PERK, or calreticulin-blocking peptide. A docetaxel-resis-
tant cell line was selected (MDR-1+, CD133+) by contin-
uous exposure to docetaxel. These cells, while resistant
to direct cytostatic effects of docetaxel, were not resistant
to the chemomodulatory effects that resulted in enhance-
ment of CTL killing. Here, we provide an operational
definition of “immunogenic modulation,” where exposure
of tumor cells to nonlethal/sublethal doses of chemother-
apy alters tumor phenotype to render the tumor more
sensitive to CTL killing. These observations are distinct
and complementary to immunogenic cell death and high-
light a mechanism whereby chemotherapy can be used in
combination with immunotherapy.
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